Filing identity and reporting period
Important mismatch: The supplied filing is Isoray, Inc.’s Form 10-Q, filed November 14, 2022, for the quarter ended September 30, 2022. It is not identified as a Perspective Therapeutics filing. The figures below summarize the supplied Isoray filing; verify the intended issuer and period before relying on them.
Business context
Isoray manufactures and sells Cesium-131 brachytherapy products, including Cesium Blu. The quarter is the first quarter of its fiscal 2023. The company reported no international revenue in the quarter.
Financial performance and liquidity
| Metric | Quarter ended Sep. 30, 2022 | Prior-year quarter |
|---|---|---|
| Net sales | $1.717 million | $2.564 million |
| Gross profit / margin | $0.414 million / 24% | $1.029 million / 40% |
| Operating expenses | $4.622 million | $3.303 million |
| Operating loss | $4.208 million | $2.274 million |
| Net loss | $4.068 million; $0.03 per share | $2.243 million; $0.02 per share |
| Cash used in operations | $1.763 million | $2.084 million |
At September 30, cash and cash equivalents were $18.989 million, short-term U.S. Treasury investments were $35.123 million, and restricted cash was $0.182 million. Working capital was $53.539 million; the current ratio was 14.38. Total liabilities were $4.836 million, including $0.458 million of lease liabilities; the filing reports no conventional borrowing balance. The quarter’s $36.901 million decrease in cash, cash equivalents, and restricted cash primarily reflected $35.076 million of Treasury purchases, rather than operating cash use alone.
Material changes and management commentary
- Sales declined 33% year over year. Management attributed the decline principally to a temporary Cesium-131 supply interruption from mid-August to early September, following an unplanned disruption at one Russian reactor while the other was undergoing planned maintenance. Regular shipments resumed September 7.
- Prostate revenue fell 41% to $1.167 million; other revenue fell 7% to $0.550 million. Prostate treatments represented 68% of sales, versus 77% a year earlier.
- Gross margin fell to 24%, as lower sales left fixed overhead against reduced volume. General and administrative expense rose 69%, largely due to legal, banking, and diligence costs associated with the proposed Viewpoint merger, as well as other expense increases.
- The former medical director, also historically the largest prostate customer, resigned September 20 and had not placed orders after supply resumed; the company reported no orders from him in October or November. Three customers represented about 48% of quarterly revenue, with one contributing about 23%.
Outlook, transaction, and risks
- Management targeted 25% revenue growth in fiscal 2023, but said the company missed that target in the first three months. It estimated cash and cash equivalents would fund Isoray’s operating needs for the next 12 months, excluding Viewpoint’s needs.
- Management estimated cash-flow break-even in three to four years if its growth assumptions are achieved and the merger does not add expenses. It cautioned that if the merger closes, the growth target would not cover the added costs and additional capital would likely be needed.
- The proposed Viewpoint merger remained subject to approvals and other closing conditions. Viewpoint shareholders were expected to own approximately 49% of the combined company on a fully diluted basis. Isoray also described a proposed $6 million loan to Viewpoint at 15% interest, due December 31, 2023, secured by intellectual property; definitive terms had not been agreed.
- Key risks include dependence on Russian isotope supply, potential effects of sanctions, transport and reactor disruptions, concentrated customers, competition and COVID-related procedure delays. The company also reported rejection of all claims in its directional-dosing patent application and was assessing next steps.
Investor verification points
- Confirm whether the intended filing is Isoray’s Q1 FY2023 10-Q or a Perspective Therapeutics filing.
- Check the subsequent status and final terms of the Viewpoint merger and proposed loan, including financing needs and potential dilution.
- Track whether isotope supply remains reliable and whether the former major customer resumes ordering.
- Assess revenue performance against the fiscal 2023 growth target and the assumptions behind management’s cash runway and break-even estimates.
- Review customer concentration and the effect of the reduced gross margin on future operating cash needs.